Quanterix Corporation QTRX

Company Overview

Quanterix Corporation (NASDAQ: QTRX) is a life sciences company focused on ultra-sensitive biomarker detection technologies used in research and clinical applications. The company operates within the diagnostics, biotechnology tools, and precision medicine industries, with a primary emphasis on enabling earlier disease detection and more precise monitoring of neurological disorders, oncology, inflammation, infectious disease, and other conditions. Its core revenue drivers include instrument sales, consumables, assay kits, and laboratory services tied to its proprietary digital biomarker analysis platforms.

The company is best known for its Simoa (Single Molecule Array) technology platform, which is designed to detect proteins and biomarkers at concentrations significantly below the limits of conventional immunoassay technologies. Quanterix serves pharmaceutical companies, academic research institutions, contract research organizations, and healthcare-related laboratories. Originally founded in 2007 as a spinout from research conducted at Tufts University, the company evolved from a specialized biomarker instrumentation provider into a broader precision health and translational diagnostics platform company through internal development, commercial expansion, and targeted acquisitions.